Andersson, M, Bagby, JR, Dyrehag, L et al. · European journal of pain (London, England) · 1998 · DOI
Researchers tested whether a staphylococcus toxoid vaccine could help people with fibromyalgia and chronic fatigue syndrome. In this study of 28 patients, those who received the vaccine showed more improvement in fatigue, pain, and mood than those who received placebo injections. In a follow-up of 23 patients treated for 2–6 years, about half were able to return to half-time or full-time work.
This study explores immunological approaches to CFS/FM symptom reduction, suggesting that targeted vaccination might address underlying pathophysiology rather than just symptom management. Long-term functional recovery (50% return to work) would represent a meaningful clinical outcome if validated in larger cohorts.
This study does not prove staphylococcus toxoid is effective for CFS or FM broadly, as it was small (n=28) and conducted in 1998 with limited replication since. It does not establish mechanism of action, optimal dosing, or which patient subgroups might benefit. The 2–6 year follow-up design makes it unclear which treatment period(s) drove improvement or whether benefits persist.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →